Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory Diseases
Valero-Martínez, Cristina (Hospital Universitario de la Princesa (Madrid))
Pardines-Ortiz, Marisa (Hospital Universitario de la Princesa (Madrid))
Montes, Nuria (Hospital Universitario de la Princesa (Madrid))
Dauden, Esteban (Hospital Universitario de la Princesa (Madrid))
Fernández-Gutiérrez, B. (Hospital Clínico San Carlos (Madrid))
García-Planella, Esther (Institut de Recerca Sant Pau)
Gomollón, Fernando (Hospital Clínico Universitario Lozano Blesa IIS Aragón)
Gratacós, Jordi (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Marsal, Sara (Hospital Universitari Vall d'Hebron)
Lamana, Amalia (Hospital Universitario de la Princesa (Madrid))
García-Vicuña, Rosario (Hospital Universitario de la Princesa (Madrid))
González-Alvaro, Isidoro (Hospital Universitario de la Princesa (Madrid))
Triguero-Martínez, Ana (Hospital Universitario de la Princesa (Madrid))
Pérez-Venegas, José J. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Julià Cano, Antonio (Hospital Universitari Vall d'Hebron)
Institut de Recerca Sant Pau

Date:	2025
Abstract:	Galectin-1 and -9 (Gal1/9) are essential mediators of immune-inflammatory responses, which makes these proteins potential biomarkers for immune-mediated diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis (PS), psoriatic arthritis (PsA), inflammatory bowel disease, and systemic lupus erythematosus (SLE). Our aim was to evaluate plasma Gal1/9 differences between IMID patients and healthy donors (HD). We analyzed 980 plasma samples divided into two analytical cohorts (600 discovery group and 380 validation group). Generalized linear models estimated Gal1/9 levels, adjusting for sex, age, storage time, and plate variability. In the overall IMID group, plasma Gal1 levels were comparable to those of HD, while Gal9 levels were significantly elevated. Levels varied across individual diseases: SLE patients consistently showed the highest Gal1/9 levels compared to both HD and other IMIDs, and RA patients had elevated Gal9 levels versus HD. Both Gal1 and Gal9 plasma levels correlated positively with higher disease activity, and Gal1 was higher in patients with longer disease duration. After adjustment for these confounders, SLE and RA patients maintained the highest Gal9 levels compared to HD. Our study demonstrates that Gal1 and Gal9 are differentially expressed across IMIDs, with particularly elevated levels in SLE, and both galectins are associated with disease activity.
Grants:	Instituto de Salud Carlos III PI21/00526 Instituto de Salud Carlos III PI24/00138
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Galectin-1 ; Galectin-9 ; Biomarkers ; Immune-mediated inflammatory diseases
Published in:	International journal of molecular sciences, Vol. 26, Num. 18 (September 2025) , art. 9087, ISSN 1422-0067

DOI: 10.3390/ijms26189087
PMID: 41009653

15 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles